Drug intelligence / Profile preview

FLAMOD

Development stage: Phase 1
Lead developer: Inserm
Modality: Recombinant Proteins and Enzymes
Administration: Inhalation

Overview

FLAMOD is a GMP-grade recombinant flagellin that functions as a Toll-like receptor 5 (TLR5) agonist. Developed by the Institut National de la Santé et de la Recherche Médicale (INSERM) in France, it is designed for administration via aerosol to stimulate the innate immune system within the respiratory tract. By activating TLR5 on lung epithelial cells and dendritic cells, FLAMOD triggers a transient inflammatory response characterized by cytokine production and neutrophil recruitment, which aims to enhance the host's defense against bacterial and viral pathogens. It is primarily being investigated for the prevention and treatment of respiratory infections, including pneumonia, particularly in immunocompromised or high-risk populations.

Other names: GMP-grade flagellinflagellin

Targets

TLR5

Beyond the preview

Go deeper on FLAMOD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FLAMOD.

Explore the full profile